252 related articles for article (PubMed ID: 35698895)
1. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia.
Pirillo A; Catapano AL
Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895
[TBL] [Abstract][Full Text] [Related]
2. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
Doggrell SA
Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805
[No Abstract] [Full Text] [Related]
3. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
Khoury E; Croteau L; Lauzière A; Gaudet D
Future Cardiol; 2022 Jun; 18(6):507-518. PubMed ID: 35469449
[TBL] [Abstract][Full Text] [Related]
4. Evinacumab for the treatment of homozygous familial hypercholesterolemia.
Gao Y; Zhang B; Yang J
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876
[TBL] [Abstract][Full Text] [Related]
5. Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
[TBL] [Abstract][Full Text] [Related]
6. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C
Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082
[TBL] [Abstract][Full Text] [Related]
7. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
[TBL] [Abstract][Full Text] [Related]
8. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
[TBL] [Abstract][Full Text] [Related]
9. Evinacumab: Mechanism of action, clinical, and translational science.
Dingman R; Bihorel S; Gusarova V; Mendell J; Pordy R
Clin Transl Sci; 2024 Jun; 17(6):e13836. PubMed ID: 38845393
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
Pirillo A; Catapano AL; Norata GD
Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
[TBL] [Abstract][Full Text] [Related]
11. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
White RT; Sankey KH; Nawarskas JJ
Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085
[TBL] [Abstract][Full Text] [Related]
12. Evinacumab for treatment of familial hypercholesterolemia.
Warden BA; Duell PB
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):739-751. PubMed ID: 34253139
[No Abstract] [Full Text] [Related]
13. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
Bajaj A; Cuchel M
J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies for familial hypercholesterolemia.
Mohamed F; Seedat F; Raal FJ
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
[TBL] [Abstract][Full Text] [Related]
15. Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia.
Duell PB; Warden BA
Ther Apher Dial; 2022 Dec; 26 Suppl 1():12-17. PubMed ID: 36468314
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
Mohamed F; Botha TC; Raal FJ
Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
[TBL] [Abstract][Full Text] [Related]
17. Marked plaque regression in homozygous familial hypercholesterolemia.
Reeskamp LF; Nurmohamed NS; Bom MJ; Planken RN; Driessen RS; van Diemen PA; Luirink IK; Groothoff JW; Kuipers IM; Knaapen P; Stroes ESG; Wiegman A; Hovingh GK
Atherosclerosis; 2021 Jun; 327():13-17. PubMed ID: 34004483
[TBL] [Abstract][Full Text] [Related]
18. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj A; Cuchel M
Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia.
Pu X; Sale M; Yang F; Zhang Y; Davis JD; Al-Huniti N
CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1412-1421. PubMed ID: 34585515
[TBL] [Abstract][Full Text] [Related]
20. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.
Raal FJ; Rosenson RS; Reeskamp LF; Kastelein JJP; Rubba P; Duell PB; Koseki M; Stroes E; Ali S; Banerjee P; Chan KC; Khilla N; McGinniss J; Pordy R; Zhang Y; Gaudet D
JACC Adv; 2023 Nov; 2(9):100648. PubMed ID: 38938723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
